Bactiguard Holding (BACTI-B) Fair Value & Analysis
Healthcare · SE · Market cap 568M SEK
Fair value as of: Jul 12, 2026
From 3 valuation models · updated 9 days ago
Share price −4.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 14.75 – kr 34.70 · fair‑value band kr 8.92 – kr 17.42 · the kr 15.80 price screens above the kr 13.17 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bactiguard Holding (BACTI-B) currently trades at kr 15.80, while our model-based Fair Value estimate is kr 13.17, implying the stock looks roughly 16.7% overvalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Bactiguard Holding generated revenue of 201M SEK at a net margin of -4.3%. Revenue declined 28.1% year over year. It earns a return on equity of -2.8%. Net debt stands at 119M SEK. Fundamentals as of Jul 12, 2026
Our scenario range runs from kr 8.92 (bear case) to kr 17.42 (bull case); at kr 15.80, the current price sits within that range. The share trades about 54% below its 52-week high and 16% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -17%, BACTI-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company was founded in 2005 …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bactiguard Holding reported revenue of kr 216M in FY2025 versus kr 169M in FY2021, a compound +6.2%/yr. Reported net income was −kr 7.8M in FY2025.
Is BACTI-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $90.53 | $79.67 | -12% |
| Stryker Corporation SYK | $310.00 | $186.28 | -40% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.98 | $10.24 | -62% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bactiguard Holding (BACTI-B) undervalued?
What is the fair value of BACTI-B?
What is the quality score of BACTI-B?
What is the revenue of Bactiguard Holding (BACTI-B)?
What is the net profit margin of BACTI-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Bactiguard Holding analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.